A new study finds early humans ate tough grasses and tubers long before their teeth adapted, suggesting behavior, not biology, drove human evolution.

The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

C3.ai's CEO and founder, Tom Siebel, has announced his decision to step down once a new CEO is in place. C3.ai could go two different ways with its CEO search. 10 stocks we like better than C3.ai › C3 ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

Segment operating income2 in the second quarter of 2025 was $172 million and segment operating margin2 was 5.6%, compared to $203 million and 6.8%, respectively, in the second quarter of 2024. The ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of C3.ai's market ...

C3.ai announced today that CEO Tom Siebel would be stepping down and that the company was in the process of looking for its ...

The stocks bucked a mostly optimistic broader market, with the tech-heavy Nasdaq and the S&P 500 both up by 0.18 percent and ...